| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 02/27/2013 | EP2560658A2 Methods of enhancing antibody-dependent cellular cytotoxicity |
| 02/27/2013 | EP2540745A9 Fully humanized anti-her2 antibody, preparation method and use thereof |
| 02/27/2013 | CN102947339A Assay for identification of LRRK2 inhibitors |
| 02/27/2013 | CN102947338A Neutralizing prolactin receptor antibodies and their therapeutic use |
| 02/27/2013 | CN102947337A Methods for treating colorectal cancer |
| 02/27/2013 | CN102947336A Methods of treating diabetes with dll4 antagonists |
| 02/27/2013 | CN102947335A Anti-polyubiquitin antibodies and methods of use |
| 02/27/2013 | CN102947334A Antibodies for treatment of clostridium difficile-associated infection and disease |
| 02/27/2013 | CN102947333A 抗体组合物 Antibody composition |
| 02/27/2013 | CN102946906A Production of heteromultimeric proteins |
| 02/27/2013 | CN102946903A High concentration antibody formulations |
| 02/27/2013 | CN102946902A Bispecific antibodies |
| 02/27/2013 | CN102946899A Pharmaceutical composition |
| 02/27/2013 | CN102944684A A and B-type blood type resistant sizing reagent |
| 02/27/2013 | CN102943067A Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| 02/27/2013 | CN102943066A Human apolipoprotein B100 (ApoB100) monoclonal antibody and chemiluminescence immune assay determination kit adopting the human ApoB100 monoclonal antibody |
| 02/27/2013 | CN102942631A Humanized anti-cmet antagonists |
| 02/27/2013 | CN102942630A Anti-osteopontin antibody |
| 02/27/2013 | CN102942629A Humanized antibody for resisting severe fever with thrombocytopenia syndrome bunyavirus (SFTSV) |
| 02/27/2013 | CN102942628A Co-production method for extracting bioactive substances from pig blood |
| 02/27/2013 | CN102942627A Immune affinity precipitation method for purification of antibodies |
| 02/27/2013 | CN102942531A Preparation method and applications of melamine derivative and melamine monoclonal antibody |
| 02/27/2013 | CN102942519A Nitenpyram hapten, artificial antigen and antibody, their preparation methods and application thereof |
| 02/27/2013 | CN102940875A Paa protein, antibody prepared from the same, and application thereof |
| 02/27/2013 | CN102492671B 5-enolpyruvylshikimate-3-phosphate synthase (EPSPS) polypeptide antigen and its preparation method and application |
| 02/27/2013 | CN102079788B Method for detecting sulfanilamide medicine and special enzyme-linked immunoassay reagent kit thereof |
| 02/27/2013 | CN102010469B Hyaluronic acid resistance monoclonal antibody and application thereof |
| 02/27/2013 | CN101921336B Monoclonal antibody against human alpha1 acid glycoprotein and preparation method thereof |
| 02/27/2013 | CN101578295B Novel antigens and antibodies associated to pancreatic ductal adenocarcinoma |
| 02/27/2013 | CN101463084B Gene engineering monoclonal antibody combined with A-beta oligomer specificity |
| 02/26/2013 | US8383919 Highly fluorescent peptide-metallic nanoclusters as bio-probes and methods of synthesis thereof |
| 02/26/2013 | US8383802 Nucleic acids encoding antibodies that bind factor D |
| 02/26/2013 | US8383799 Translocation and mutant ROS kinase in human non-small cell lung carcinoma |
| 02/26/2013 | US8383788 For therapy of cancer or tumorous growth |
| 02/26/2013 | US8383781 Anti-NIK antibodies and uses thereof |
| 02/26/2013 | US8383780 Antibodies to TGFβ |
| 02/26/2013 | US8383779 Human antibodies that bind mesothelin, and uses thereof |
| 02/26/2013 | US8383778 IL-1 binding proteins |
| 02/26/2013 | US8383777 13-transmembrane protein expressed in prostate cancer |
| 02/26/2013 | US8383774 Collectin fusion proteins comprising TNF or trail |
| 02/26/2013 | US8383772 Ang-(1-7) receptor agonist |
| 02/26/2013 | US8383767 Immunogenic protein carrier containing an antigen presenting cell binding domain and a cysteine-rich domain |
| 02/26/2013 | US8383358 Use of 2 anti-SPARC antibodies to predict response to melanoma chemotherapy |
| 02/26/2013 | US8383351 Antibody to inhibin/ activin β-B subunit |
| 02/26/2013 | US8383126 Bacterial pheromones and uses thereof |
| 02/26/2013 | US8383125 Antimicrobial protein |
| 02/26/2013 | US8383122 Process for preparing purified drug conjugates |
| 02/26/2013 | US8383121 Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus H5-subtype or N1-subtype and uses thereof |
| 02/26/2013 | US8383120 Concomitant treatment of rheumatoid arthritis with anti-TNF-alpha antibodies and methotrexate |
| 02/26/2013 | US8383119 Biological substance nesfatin and its related substances and uses thereof |
| 02/26/2013 | US8383118 Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1 |
| 02/26/2013 | US8383117 CD44E tumor specific antibody |
| 02/26/2013 | US8383116 Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy |
| 02/26/2013 | US8383115 Engineered scFv against bovine herpes virus type I |
| 02/26/2013 | US8383113 Anti-ADDL antibodies and uses thereof |
| 02/26/2013 | US8383112 Targeting VEGF-B regulation of fatty acid transporters to modulate human diseases |
| 02/26/2013 | US8383111 Inotropic antibodies and therapeutic uses thereof |
| 02/26/2013 | US8383109 Optimized Fc variants and methods for their generation |
| 02/26/2013 | US8383108 Therapeutic uses of monoclonal antibodies to the angiotensin-II type 1 receptor |
| 02/26/2013 | US8383107 Single domain brain-targeting antibody fragments derived from llama antibodies |
| 02/26/2013 | US8383081 Anti-CD74 immunoconjugates and methods of use |
| 02/26/2013 | CA2674885C Anti-ige vaccines |
| 02/26/2013 | CA2674837C Anti-ige vaccines |
| 02/26/2013 | CA2633345C A method of affinity separation and ligands for use therein |
| 02/26/2013 | CA2536256C Targeting of tumor vasculature using radiolabelled antibody l19 against fibronectin ed-b |
| 02/26/2013 | CA2524399C Optimized fc variants and methods for their generation |
| 02/26/2013 | CA2389644C A novel polypeptide hormone phosphatonin |
| 02/26/2013 | CA2327586C Fap.alpha.-specific antibody with improved producibility |
| 02/26/2013 | CA2324648C Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items |
| 02/26/2013 | CA2324381C An integrin heterodimer and a subunit thereof |
| 02/21/2013 | WO2013025944A1 Inhibition of angiogenesis in refractory tumors |
| 02/21/2013 | WO2013025853A1 Neuregulin antibodies and uses thereof |
| 02/21/2013 | WO2013025779A1 Anti-b7-h4 antibodies and their uses |
| 02/21/2013 | WO2013025700A1 Phosphocofilin: cofilin co-localization intensity as a predictor of metastic recurrence |
| 02/21/2013 | WO2013025479A1 Jaml specific binding agents, antibodies, and uses related thereto |
| 02/21/2013 | WO2013025467A2 Methods of treating hematological proliferative disorders by targeting epha3 expressed on aberrant vasculature in bone marrow |
| 02/21/2013 | WO2013025446A2 Anti-fzd10 monoclonal antibodies and methods for their use |
| 02/21/2013 | WO2013024905A1 Combination drug of antibody against lipopolysaccharide of pseudomonas aeruginosa and antibacterial agent |
| 02/21/2013 | WO2013024867A1 Antibody and use thereof |
| 02/21/2013 | WO2013024517A1 Method for testing for, preventing, and treating infectious disease aspergillus fumigatus; and composition |
| 02/21/2013 | WO2013024157A2 Combinations of host targeting agents for the treatment and the prevention of hcv infection |
| 02/21/2013 | WO2013024156A2 Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection |
| 02/21/2013 | WO2013024155A1 Combinations of anti-hcv-entry factor antibodies and direct acting antivirals for the treatment and the prevention of hcv infection |
| 02/21/2013 | WO2013024100A2 Methods for diagnosing and treating medical conditions associated with oxidative stress |
| 02/21/2013 | WO2013024097A1 Combination therapy with an anti - cd19 antibody and a nitrogen mustard |
| 02/21/2013 | WO2013024095A1 Combination therapy with an anti - cd19 antibody and a purine analog |
| 02/21/2013 | WO2013024059A2 Modified proteins and peptides |
| 02/21/2013 | WO2013023557A1 Humanized monoclone antibody of macrophage inhibition factor 1 and use thereof |
| 02/21/2013 | WO2013023251A1 Soluble polypeptides |
| 02/21/2013 | WO2011160119A8 Anti-gd2 antibodies |
| 02/21/2013 | WO2011116954A8 Prophylaxis of colorectal and gastrointestinal cancer |
| 02/21/2013 | US20130046081 Fully human monoclonal antibody to vegf, preparation method and use thereof |
| 02/21/2013 | US20130046079 Mouse lambda light chain locus |
| 02/21/2013 | US20130046078 Anti-fgfr3 antibodies and methods using same |
| 02/21/2013 | US20130045917 Method of selecting polypeptide sequence, and metal oxide or silicon-containing compound binding peptide and use thereof |
| 02/21/2013 | US20130045895 Binding domains |
| 02/21/2013 | US20130045543 Novel muc1 antibody |
| 02/21/2013 | US20130045537 Methods and compositions relating to multiciliate cell differentiation |
| 02/21/2013 | US20130045493 Diagnosis and treatment of gluten-induced autoimmune diseases |
| 02/21/2013 | US20130045490 Antibody against mucin 1 (muc1) protein and use of same |